Real-Time Measurement of Antiglaucoma Drugs in Porcine Eyes Using Boron-Doped Diamond Microelectrodes

• Published in: ACS sensors Vol. 9; no. 2; pp. 781 - 788
• Main Authors: Ogata, Genki, Yoneda, Mao, Ogawa, Risa, Hanawa, Ai, Asai, Kai, Yamagishi, Reiko, Honjo, Megumi, Aihara, Makoto, Einaga, Yasuaki
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 23.02.2024
• Subjects: eye drops; pharmacokinetics; boron-doped diamond; glaucoma; drug monitoring
• ISSN: 2379-3694; 2379-3694
• DOI: 10.1021/acssensors.3c02088

The primary treatment for glaucoma, the most common cause of intermediate vision impairment, involves administering ocular hypotensive drugs in the form of topical eye drops. Observing real-time changes in the drugs that pass through the cornea and reach the anterior chamber of the eye is crucial for improving and developing safe, reliable, and effective medical treatments. Traditional methods for measuring temporal changes in drug concentrations in the aqueous humor employ separation analyzers such as LC–MS/MS. However, this technique requires multiple measurements on the eyes of various test subjects to track changes over time with a high temporal resolution. To address this issue, we have developed a measurement method that employs boron-doped diamond (BDD) microelectrodes to monitor real-time drug concentrations in the anterior chamber of the eye. First, we confirmed the electrochemical reactivity of 13 antiglaucoma drugs in a phosphate buffer solution with a pH of 7.4. Next, we optimized the method for continuous measurement of timolol maleate (TIM), a sympathetic beta-receptor antagonist, and generated calibration curves for each BDD microelectrode using aqueous humor collected from enucleated porcine eyes. We successfully demonstrated the continuous ex vivo monitoring of TIM concentrations in the anterior chambers of these enucleated porcine eyes. The results indicate that changes in intracameral TIM concentrations can be monitored through electrochemical measurements using BDD microelectrodes. This technique holds promise for future advancements in optimizing glaucoma treatment and drug administration strategies.